AccuLine

AccuLine is a digital healthcare company dedicated to improving early detection of coronary artery disease (CAD) to help prevent heart attacks, which are a leading cause of death worldwide. The company develops innovative, non-invasive diagnostic solutions that fill significant gaps in current CAD screening methods. Their flagship product, CORA, is a tabletop touchscreen device that offers a quick and risk-free examination for early CAD detection. CORA utilizes two novel bio-signals from the heart's electrical activity, enhanced by AI-powered signal processing and proprietary augmented waveform display technology. This allows for the simultaneous measurement of various biological indicators, such as cardiac electrical activity and blood oxygen saturation, to assess coronary artery health. Clinical studies indicate that CORA can differentiate between individuals with and without significant coronary heart disease with approximately 85% sensitivity and specificity. AccuLine's leadership team includes CEO Moshe Barel, along with Co-Founders Prof. Aharon Frimerman and Benny Shani, who bring extensive experience in cardiology and technology development. The company has partnered with the Mayo Clinic to advance CORA's development and clinical validation for the U.S. market, aiming to establish it as a preferred diagnostic tool for healthcare providers.

• Employees 13
• Founded 2022